The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant omicron is now under investigation. We evaluated cross-neutralizing activity against omicron in coronavirus disease 2019 (COVID-19) convalescent patients (n = 23) who had received 2 doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Intriguingly, after the second vaccination, the neutralizing antibody titers of subjects against SARS-CoV-2 variants, including omicron, all became seropositive, and significant fold-increases (21.1-52.0) were seen regardless of the disease severity. Our findings thus demonstrate that 2 doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against omicron.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129189 | PMC |
| http://dx.doi.org/10.1093/infdis/jiac178 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patients.
Res Sq
December 2024
Biology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
As of May 2023, the public health emergency of COVID-19 was lifted across the globe. However, SARS-CoV-2 infections continue to be recorded worldwide. This situation has been attributed to the ability of the virus to evade host immune responses including neutralizing antibody-derived Immunity.
View Article and Find Full Text PDFHuman adenovirus species B knob proteins as immunogens for inducing cross-neutralizing antibody responses.
mSphere
December 2024
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
The re-emerging human adenovirus (HAdV) types 3, 7, 14, and 55 of species B have caused severe or even fatal acute respiratory disease. Therefore, the development of multivalent vaccines against HAdV types 3, 7, 14, and 55 remains an important goal. In our previous study, we identified a cross-neutralizing epitope that induced broadly reactive monoclonal neutralizing antibodies against the knob proteins of HAdV types 7, 11, 14, and 55.
View Article and Find Full Text PDFMosquito-independent milk-associated transmission of zoonotic Wesselsbron virus in sheep.
PLoS Pathog
December 2024
Institute of Virology and Immunology (IVI), Mittelhäusern, Switzerland.
Wesselsbron virus (WSLV) is a zoonotic, mosquito-borne orthoflavivirus endemic to sub-Saharan Africa, causing abortions and stillbirths in small ruminants. The life cycle of WSLV involves Aedes mosquitoes and various wildlife and domestic animals. Seminal studies in the 1950s have shown the zoonotic potential of WSLV, notably in accidental infections of laboratory workers exposed to infected material.
View Article and Find Full Text PDFImmune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.
Vaccine
January 2025
Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. Electronic address:
Article Synopsis
Developing a human monoclonal antibody combination CRM25 to prevent rabies after exposure.
Int J Antimicrob Agents
December 2024
Division of Monoclonal Antibody Products, National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, China. Electronic address:
Article Synopsis
- The objective of this study was to explore the use of monoclonal antibodies (mAbs) as a safer and more effective alternative to traditional rabies immunoglobulin (RIG) for post-exposure rabies treatment.
- Researchers developed a mAb combination called CRM25, made from two non-competing human mAbs, RM02 and RM05, which target different parts of the rabies virus.
- Results showed that CRM25 effectively neutralized various rabies virus strains and demonstrated protective abilities in animal models, suggesting it could be a promising candidate for rabies treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!